Evaluation of possible drug-drug interaction between gadoxetic acid and erythromycin as an inhibitor of organic anion transporting peptides (OATP)
Purpose To evaluate if erythromycin compromises liver‐specific enhancement of gadoxetic acid; both compounds competing in organic anion transporting peptides (OATP) ‐mediated hepatocytic uptake. Materials and Methods The study was approved by institutional review board. Twelve healthy subjects (nine...
Saved in:
| Published in | Journal of magnetic resonance imaging Vol. 33; no. 2; pp. 409 - 416 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.02.2011
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1053-1807 1522-2586 1522-2586 |
| DOI | 10.1002/jmri.22458 |
Cover
| Abstract | Purpose
To evaluate if erythromycin compromises liver‐specific enhancement of gadoxetic acid; both compounds competing in organic anion transporting peptides (OATP) ‐mediated hepatocytic uptake.
Materials and Methods
The study was approved by institutional review board. Twelve healthy subjects (nine men, three woman; mean age, 38.7 years) were examined twice by MR imaging with prior administration of NaCl solution (placebo) or 1000 mg of erythromycin following a randomized sequence. Gadoxetic acid (0.025 mmol/kg body weight) was administered 15 min after the end of infusions. Pre‐ and 20 min postcontrast two‐dimensional gradient‐recalled‐echo sequences were acquired. Relative enhancements of liver parenchyma and ratio of means were calculated from signal intensity measurements. Plasma levels of gadoxetic acid and erythromycin were determined and given in geometric means and coefficients of variation (CV).
Results
Concentration of erythromycin directly after end of infusion was 13.9 mg/L (CV 14.9%). Gadolinium plasma concentrations 5 min after gadoxetic acid administration were 138.7 μmol/L (CV 20.4%) after erythromycin infusion and 129.6 μmol/L (CV 22.8%) after placebo. Mean relative enhancements of liver parenchyma were 88.1 (SD 24.9%) after erythromycin infusion and 92.6 (SD 17.9%) after placebo. Ratio of relative enhancements was 0.951 (95% confidence interval, 0.833; 1.061; statistically not significant).
Conclusion
Coadministration of erythromycin has no effect on gadoxetic acid enhanced liver MR imaging. J. Magn. Reson. Imaging 2011;33:409–416. © 2011 Wiley‐Liss, Inc. |
|---|---|
| AbstractList | To evaluate if erythromycin compromises liver-specific enhancement of gadoxetic acid; both compounds competing in organic anion transporting peptides (OATP) -mediated hepatocytic uptake.PURPOSETo evaluate if erythromycin compromises liver-specific enhancement of gadoxetic acid; both compounds competing in organic anion transporting peptides (OATP) -mediated hepatocytic uptake.The study was approved by institutional review board. Twelve healthy subjects (nine men, three woman; mean age, 38.7 years) were examined twice by MR imaging with prior administration of NaCl solution (placebo) or 1000 mg of erythromycin following a randomized sequence. Gadoxetic acid (0.025 mmol/kg body weight) was administered 15 min after the end of infusions. Pre- and 20 min postcontrast two-dimensional gradient-recalled-echo sequences were acquired. Relative enhancements of liver parenchyma and ratio of means were calculated from signal intensity measurements. Plasma levels of gadoxetic acid and erythromycin were determined and given in geometric means and coefficients of variation (CV).MATERIALS AND METHODSThe study was approved by institutional review board. Twelve healthy subjects (nine men, three woman; mean age, 38.7 years) were examined twice by MR imaging with prior administration of NaCl solution (placebo) or 1000 mg of erythromycin following a randomized sequence. Gadoxetic acid (0.025 mmol/kg body weight) was administered 15 min after the end of infusions. Pre- and 20 min postcontrast two-dimensional gradient-recalled-echo sequences were acquired. Relative enhancements of liver parenchyma and ratio of means were calculated from signal intensity measurements. Plasma levels of gadoxetic acid and erythromycin were determined and given in geometric means and coefficients of variation (CV).Concentration of erythromycin directly after end of infusion was 13.9 mg/L (CV 14.9%). Gadolinium plasma concentrations 5 min after gadoxetic acid administration were 138.7 μmol/L (CV 20.4%) after erythromycin infusion and 129.6 μmol/L (CV 22.8%) after placebo. Mean relative enhancements of liver parenchyma were 88.1 (SD 24.9%) after erythromycin infusion and 92.6 (SD 17.9%) after placebo. Ratio of relative enhancements was 0.951 (95% confidence interval, 0.833; 1.061; statistically not significant).RESULTSConcentration of erythromycin directly after end of infusion was 13.9 mg/L (CV 14.9%). Gadolinium plasma concentrations 5 min after gadoxetic acid administration were 138.7 μmol/L (CV 20.4%) after erythromycin infusion and 129.6 μmol/L (CV 22.8%) after placebo. Mean relative enhancements of liver parenchyma were 88.1 (SD 24.9%) after erythromycin infusion and 92.6 (SD 17.9%) after placebo. Ratio of relative enhancements was 0.951 (95% confidence interval, 0.833; 1.061; statistically not significant).Coadministration of erythromycin has no effect on gadoxetic acid enhanced liver MR imaging.CONCLUSIONCoadministration of erythromycin has no effect on gadoxetic acid enhanced liver MR imaging. To evaluate if erythromycin compromises liver-specific enhancement of gadoxetic acid; both compounds competing in organic anion transporting peptides (OATP) -mediated hepatocytic uptake. The study was approved by institutional review board. Twelve healthy subjects (nine men, three woman; mean age, 38.7 years) were examined twice by MR imaging with prior administration of NaCl solution (placebo) or 1000 mg of erythromycin following a randomized sequence. Gadoxetic acid (0.025 mmol/kg body weight) was administered 15 min after the end of infusions. Pre- and 20 min postcontrast two-dimensional gradient-recalled-echo sequences were acquired. Relative enhancements of liver parenchyma and ratio of means were calculated from signal intensity measurements. Plasma levels of gadoxetic acid and erythromycin were determined and given in geometric means and coefficients of variation (CV). Concentration of erythromycin directly after end of infusion was 13.9 mg/L (CV 14.9%). Gadolinium plasma concentrations 5 min after gadoxetic acid administration were 138.7 μmol/L (CV 20.4%) after erythromycin infusion and 129.6 μmol/L (CV 22.8%) after placebo. Mean relative enhancements of liver parenchyma were 88.1 (SD 24.9%) after erythromycin infusion and 92.6 (SD 17.9%) after placebo. Ratio of relative enhancements was 0.951 (95% confidence interval, 0.833; 1.061; statistically not significant). Coadministration of erythromycin has no effect on gadoxetic acid enhanced liver MR imaging. Purpose To evaluate if erythromycin compromises liver‐specific enhancement of gadoxetic acid; both compounds competing in organic anion transporting peptides (OATP) ‐mediated hepatocytic uptake. Materials and Methods The study was approved by institutional review board. Twelve healthy subjects (nine men, three woman; mean age, 38.7 years) were examined twice by MR imaging with prior administration of NaCl solution (placebo) or 1000 mg of erythromycin following a randomized sequence. Gadoxetic acid (0.025 mmol/kg body weight) was administered 15 min after the end of infusions. Pre‐ and 20 min postcontrast two‐dimensional gradient‐recalled‐echo sequences were acquired. Relative enhancements of liver parenchyma and ratio of means were calculated from signal intensity measurements. Plasma levels of gadoxetic acid and erythromycin were determined and given in geometric means and coefficients of variation (CV). Results Concentration of erythromycin directly after end of infusion was 13.9 mg/L (CV 14.9%). Gadolinium plasma concentrations 5 min after gadoxetic acid administration were 138.7 μmol/L (CV 20.4%) after erythromycin infusion and 129.6 μmol/L (CV 22.8%) after placebo. Mean relative enhancements of liver parenchyma were 88.1 (SD 24.9%) after erythromycin infusion and 92.6 (SD 17.9%) after placebo. Ratio of relative enhancements was 0.951 (95% confidence interval, 0.833; 1.061; statistically not significant). Conclusion Coadministration of erythromycin has no effect on gadoxetic acid enhanced liver MR imaging. J. Magn. Reson. Imaging 2011;33:409–416. © 2011 Wiley‐Liss, Inc. |
| Author | Hamm, Bernd Breuer, Josy Frericks, Bernd Huppertz, Alexander Klein, Stefan Wagner, Moritz Fels, Lueder M. Schultze-Mosgau, Marcus Sutter, Gabriele |
| Author_xml | – sequence: 1 givenname: Alexander surname: Huppertz fullname: Huppertz, Alexander email: alexander.huppertz@charite.de organization: Charité-University Hospital Berlin, Charité Campus Mitte, Department of Radiology, Berlin, Germany – sequence: 2 givenname: Josy surname: Breuer fullname: Breuer, Josy organization: Global Medical Development, Bayer Schering Pharma AG, Berlin, Germany – sequence: 3 givenname: Lueder M. surname: Fels fullname: Fels, Lueder M. organization: Clinical Pharmacology, Bayer Schering Pharma AG, Berlin, Germany – sequence: 4 givenname: Marcus surname: Schultze-Mosgau fullname: Schultze-Mosgau, Marcus organization: Clinical Pharmacology, Bayer Schering Pharma AG, Berlin, Germany – sequence: 5 givenname: Gabriele surname: Sutter fullname: Sutter, Gabriele organization: Clinical Pharmacology, Bayer Schering Pharma AG, Berlin, Germany – sequence: 6 givenname: Stefan surname: Klein fullname: Klein, Stefan organization: Global Medical Development, Bayer Schering Pharma AG, Berlin, Germany – sequence: 7 givenname: Bernd surname: Frericks fullname: Frericks, Bernd organization: Charité-University Hospital Berlin, Charité Campus Mitte, Department of Radiology, Berlin, Germany – sequence: 8 givenname: Bernd surname: Hamm fullname: Hamm, Bernd organization: Charité-University Hospital Berlin, Charité Campus Mitte, Department of Radiology, Berlin, Germany – sequence: 9 givenname: Moritz surname: Wagner fullname: Wagner, Moritz organization: Charité-University Hospital Berlin, Charité Campus Mitte, Department of Radiology, Berlin, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21274983$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kctu1DAYhS1URC-w4QGQdxSkFF_iib2sqlKKeuFSxNJynD9Tl8QOtkM7r8ETk8y0XSDExras7zuLc3bRlg8eEHpJyQElhL276aM7YKwU8gnaoYKxggm52JreRPCCSlJto92UbgghSpXiGdpmlFWlknwH_T7-ZbrRZBc8Di0eQkqu7gA3cVwW84GdzxCNXRM15FsAj5emCXeQncXGugYb32CIq3wdQ7-yzmOTpr_JvHa1yyHOySEujZ8FPwflaHwaQszOL_EAQ3YNJLx_eXj16c1z9LQ1XYIX9_ce-vb--OroQ3F2eXJ6dHhW2HIhZQGttaylouamEpwqLpQwciF4yctaEmlaqxa1kFVpCW1ZXbUlCCKqplZNxSThe-j1JneI4ecIKeveJQtdZzyEMWlZSs4oV2wiX92TY91Do4foehNX-qHGCXi7AWycCozQPiKU6HkjPW-k1xtNMPkLti6vF5hacd2_FbpRbl0Hq_-E64_nX04fnGLjuJTh7tEx8YdeVLwS-vvFif76WbFzypS-4H8ABiy1Dg |
| CitedBy_id | crossref_primary_10_1007_s00330_022_08984_0 crossref_primary_10_1016_j_jhep_2015_11_016 crossref_primary_10_1007_s11604_013_0208_6 crossref_primary_10_1016_j_mri_2012_11_006 crossref_primary_10_1186_s12880_021_00552_0 crossref_primary_10_1007_s00330_020_06726_8 crossref_primary_10_1007_s00330_012_2422_5 crossref_primary_10_1016_j_jhep_2012_01_031 crossref_primary_10_1016_j_ejphar_2011_11_048 crossref_primary_10_1007_s00330_014_3144_7 crossref_primary_10_1586_ecp_11_58 crossref_primary_10_1016_j_pharmthera_2018_04_006 crossref_primary_10_1124_dmd_114_059873 crossref_primary_10_1371_journal_pone_0197213 crossref_primary_10_1002_nbm_2946 crossref_primary_10_1124_dmd_113_055707 crossref_primary_10_2217_pgs_13_132 crossref_primary_10_1007_s00261_020_02881_0 crossref_primary_10_1016_j_clinimag_2013_11_001 crossref_primary_10_1097_RLI_0000000000000622 crossref_primary_10_1002_bdd_1907 crossref_primary_10_2217_hep_13_11 |
| Cites_doi | 10.1186/1471-2334-9-61 10.1148/radiol.2301020269 10.1124/dmd.106.014407 10.1007/s00535-009-0056-4 10.1111/j.1476-5381.2009.00430.x 10.1002/jmri.21913 10.1146/annurev.pharmtox.44.101802.121444 10.1006/bbrc.2001.4318 10.1124/jpet.102.041921 10.1007/s00210-006-0040-y 10.1148/radiol.2342040278 10.1055/s-0028-1109141 10.1111/j.1365-2125.1982.tb01437.x 10.1007/BF03189891 10.1097/01.rli.0000184756.66360.d3 10.1016/S0005-2736(02)00633-8 10.1124/dmd.106.009290 10.1002/pds.1244 10.1016/j.ijantimicag.2009.05.008 10.1074/jbc.274.24.17159 10.1148/radiol.2371031842 10.1007/BF01059558 10.1148/radiology.183.1.1549695 10.1002/jmri.22054 10.1148/radiology.195.3.7754011 10.1007/s00424-003-1168-y 10.2133/dmpk.19.171 10.1517/17425255.1.3.429 10.1002/jmri.21839 10.1097/00004424-200212000-00007 10.1016/S0022-3565(24)34879-7 10.1002/jmri.21956 10.1074/jbc.M001448200 10.1517/17425250902911463 10.1053/jhep.2002.34133 |
| ContentType | Journal Article |
| Copyright | Copyright © 2011 Wiley‐Liss, Inc. Copyright © 2011 Wiley-Liss, Inc. |
| Copyright_xml | – notice: Copyright © 2011 Wiley‐Liss, Inc. – notice: Copyright © 2011 Wiley-Liss, Inc. |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1002/jmri.22458 |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1522-2586 |
| EndPage | 416 |
| ExternalDocumentID | 21274983 10_1002_jmri_22458 JMRI22458 ark_67375_WNG_SQ92M129_N |
| Genre | article Randomized Controlled Trial Journal Article |
| GrantInformation_xml | – fundername: Bayer Healthcare AG |
| GroupedDBID | --- -DZ .3N .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 31~ 33P 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HDBZQ HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TWZ UB1 V2E V8K V9Y W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI WXSBR XG1 XV2 ZXP ZZTAW ~IA ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c4688-efcc2f15b3a753193595a8653434b808afc96b5874c01f2b7f4e5057db9d72803 |
| IEDL.DBID | DR2 |
| ISSN | 1053-1807 1522-2586 |
| IngestDate | Fri Jul 11 05:06:49 EDT 2025 Mon Jul 21 05:30:21 EDT 2025 Tue Jul 01 05:25:29 EDT 2025 Thu Apr 24 23:09:56 EDT 2025 Wed Jan 22 16:59:00 EST 2025 Wed Oct 30 09:51:45 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor Copyright © 2011 Wiley-Liss, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4688-efcc2f15b3a753193595a8653434b808afc96b5874c01f2b7f4e5057db9d72803 |
| Notes | Bayer Healthcare AG ArticleID:JMRI22458 istex:5EB793AEF086ED6C6865B3ED7D8EB3B41FFA9F04 ark:/67375/WNG-SQ92M129-N ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jmri.22458 |
| PMID | 21274983 |
| PQID | 848321392 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_848321392 pubmed_primary_21274983 crossref_primary_10_1002_jmri_22458 crossref_citationtrail_10_1002_jmri_22458 wiley_primary_10_1002_jmri_22458_JMRI22458 istex_primary_ark_67375_WNG_SQ92M129_N |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | February 2011 |
| PublicationDateYYYYMMDD | 2011-02-01 |
| PublicationDate_xml | – month: 02 year: 2011 text: February 2011 |
| PublicationDecade | 2010 |
| PublicationPlace | Hoboken |
| PublicationPlace_xml | – name: Hoboken – name: United States |
| PublicationTitle | Journal of magnetic resonance imaging |
| PublicationTitleAlternate | J. Magn. Reson. Imaging |
| PublicationYear | 2011 |
| Publisher | Wiley Subscription Services, Inc., A Wiley Company |
| Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company |
| References | Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44: 793-798. Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007; 35: 779-786. Vavricka SR, van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002; 36: 164-172. König J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 432-443. Motosugi U, Ichikawa T, Sou H, et al. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI). J Magn Reson Imaging 2009; 30: 849-854. Abe T, Kakyo M, Tokui T, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999; 274: 17159-17163. Huppertz A, Balzer T, Blakeborough A, et al; European EOB Study Group. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275. Kim YK, Kwak HS, Kim CS, Han YM. Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxectic acid. J Magn Reson Imaging 2009; 30: 437-443. Pascolo L, Petrovic S, Cupelli F, et al. Abc protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles. Biochem Biophys Res Commun 2001; 282: 60-66. Locke CS. An exact confidence interval for untransformed data for the ratio of two formulation means. J Pharmacokinet Biopharm 1984; 12: 649-655. Metz-Gercek S, Maieron A, Strauss R, Wieninger P, Apfalter P, Mittermayer H. Ten years of antibiotic consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in Austria. BMC Infect Dis 2009; 9: 61. Filippone A, Blakeborough A, Breuer J, et al. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 2010; 31: 356-364. Karlowsky JA, Lagace-Wiens PR, Low DE, Zhanel GG. Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. Int J Antimicrob Agents 2009; 34: 375-379. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005; 237: 89-98. Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 2005; 45: 689-723. Segui A, Milon D, Cormier M, Lepesant G. Erythromycin lactobionate: pharmacokinetics and uterine tissue levels. Eur J Drug Metab Pharmacokinet 1987; 12: 153-160. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-478. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40: 715-724. Koelblinger C, Schima W, Weber M, et al. Gadoxate-enhanced T 1-weighted MR cholangiography: comparison of 1.5 T and 3.0 T. Rofo 2009; 181: 587-592. Kindla J, Fromm MF, Konig J. In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions. Expert Opin Drug Metab Toxicol 2009; 5: 489-500. Elseviers MM, Ferech M, Vander Stichele RH, Goossens H; ESAC Project Group. Antibiotic use in ambulatory care in Europe (ESAC data 1997-2002): trends, regional differences and seasonal fluctuations. Pharmacoepidemiol Drug Saf 2007; 16: 115-123. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785-792. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705. Josefsson K, Bergan T, Magni L. Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base. Br J Clin Pharmacol 1982; 13: 685-691. Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 2003; 1609: 1-18. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 1999; 290: 153-157. Kiss IJ, Farago E, Kiss B, Varhelyi I. Pharmacokinetic study of rifampicin in biliary surgery. Int J Clin Pharmacol Biopharm 1978; 16: 105-109. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004; 447: 653-665. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006; 34: 1229-1236. Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005; 1: 429-445. Kato N, Yokawa T, Tamura A, Heshiki A, Ebert W, Weinmann HJ. Gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats. Invest Radiol 2002; 37: 680-684. Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000; 275: 23161-23168. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009; 30: 1042-1046. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of trans- porter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003; 304: 610-616. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 2004; 19: 171-179. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183: 59-64. 2009; 44 1982; 13 2002; 36 2010; 31 2002; 37 1987; 12 2001; 282 1992; 183 2006; 34 2009; 181 2010 2005; 234 2005; 237 1999; 290 2005; 40 2006; 372 1978; 16 2000; 275 1995; 195 2004; 447 2007; 35 2009; 158 2005; 45 2007; 16 2009; 34 2004; 230 2009; 30 2003; 304 2004; 19 1984; 12 1999; 274 2009; 9 2005; 1 2009; 5 2003; 1609 e_1_2_6_30_2 e_1_2_6_18_2 e_1_2_6_19_2 e_1_2_6_12_2 e_1_2_6_35_2 e_1_2_6_13_2 e_1_2_6_34_2 e_1_2_6_10_2 e_1_2_6_33_2 e_1_2_6_11_2 e_1_2_6_32_2 e_1_2_6_16_2 Kiss IJ (e_1_2_6_31_2) 1978; 16 e_1_2_6_17_2 e_1_2_6_38_2 e_1_2_6_14_2 e_1_2_6_37_2 e_1_2_6_15_2 e_1_2_6_36_2 e_1_2_6_20_2 e_1_2_6_8_2 e_1_2_6_7_2 e_1_2_6_9_2 e_1_2_6_29_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 e_1_2_6_5_2 e_1_2_6_23_2 e_1_2_6_2_2 e_1_2_6_22_2 e_1_2_6_21_2 van Montfoort JE (e_1_2_6_24_2) 1999; 290 e_1_2_6_28_2 e_1_2_6_27_2 e_1_2_6_26_2 e_1_2_6_25_2 |
| References_xml | – reference: Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44: 793-798. – reference: Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705. – reference: Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007; 35: 779-786. – reference: Kindla J, Fromm MF, Konig J. In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions. Expert Opin Drug Metab Toxicol 2009; 5: 489-500. – reference: Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of trans- porter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003; 304: 610-616. – reference: Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005; 1: 429-445. – reference: Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006; 34: 1229-1236. – reference: Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009; 30: 1042-1046. – reference: Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005; 237: 89-98. – reference: Elseviers MM, Ferech M, Vander Stichele RH, Goossens H; ESAC Project Group. Antibiotic use in ambulatory care in Europe (ESAC data 1997-2002): trends, regional differences and seasonal fluctuations. Pharmacoepidemiol Drug Saf 2007; 16: 115-123. – reference: Pascolo L, Petrovic S, Cupelli F, et al. Abc protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles. Biochem Biophys Res Commun 2001; 282: 60-66. – reference: Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004; 447: 653-665. – reference: König J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 432-443. – reference: Motosugi U, Ichikawa T, Sou H, et al. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI). J Magn Reson Imaging 2009; 30: 849-854. – reference: Segui A, Milon D, Cormier M, Lepesant G. Erythromycin lactobionate: pharmacokinetics and uterine tissue levels. Eur J Drug Metab Pharmacokinet 1987; 12: 153-160. – reference: Locke CS. An exact confidence interval for untransformed data for the ratio of two formulation means. J Pharmacokinet Biopharm 1984; 12: 649-655. – reference: van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 1999; 290: 153-157. – reference: Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-478. – reference: Filippone A, Blakeborough A, Breuer J, et al. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 2010; 31: 356-364. – reference: Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000; 275: 23161-23168. – reference: Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 2005; 45: 689-723. – reference: Vavricka SR, van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002; 36: 164-172. – reference: Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785-792. – reference: Kato N, Yokawa T, Tamura A, Heshiki A, Ebert W, Weinmann HJ. Gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats. Invest Radiol 2002; 37: 680-684. – reference: Metz-Gercek S, Maieron A, Strauss R, Wieninger P, Apfalter P, Mittermayer H. Ten years of antibiotic consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in Austria. BMC Infect Dis 2009; 9: 61. – reference: Abe T, Kakyo M, Tokui T, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999; 274: 17159-17163. – reference: Koelblinger C, Schima W, Weber M, et al. Gadoxate-enhanced T 1-weighted MR cholangiography: comparison of 1.5 T and 3.0 T. Rofo 2009; 181: 587-592. – reference: Josefsson K, Bergan T, Magni L. Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base. Br J Clin Pharmacol 1982; 13: 685-691. – reference: Kim YK, Kwak HS, Kim CS, Han YM. Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxectic acid. J Magn Reson Imaging 2009; 30: 437-443. – reference: Karlowsky JA, Lagace-Wiens PR, Low DE, Zhanel GG. Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. Int J Antimicrob Agents 2009; 34: 375-379. – reference: Huppertz A, Balzer T, Blakeborough A, et al; European EOB Study Group. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275. – reference: Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40: 715-724. – reference: Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183: 59-64. – reference: Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 2003; 1609: 1-18. – reference: Kiss IJ, Farago E, Kiss B, Varhelyi I. Pharmacokinetic study of rifampicin in biliary surgery. Int J Clin Pharmacol Biopharm 1978; 16: 105-109. – reference: Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 2004; 19: 171-179. – volume: 183 start-page: 59 year: 1992 end-page: 64 article-title: Preclinical evaluation of Gd‐EOB‐DTPA as a contrast agent in MR imaging of the hepatobiliary system publication-title: Radiology – volume: 13 start-page: 685 year: 1982 end-page: 691 article-title: Dose‐related pharmacokinetics after oral administration of a new formulation of erythromycin base publication-title: Br J Clin Pharmacol – volume: 1 start-page: 429 year: 2005 end-page: 445 article-title: Role of the liver‐specific transporters OATP1B1 and OATP1B3 in governing drug elimination publication-title: Expert Opin Drug Metab Toxicol – volume: 304 start-page: 610 year: 2003 end-page: 616 article-title: Inhibition of trans‐ porter‐mediated hepatic uptake as a mechanism for drug‐drug interaction between cerivastatin and cyclosporin A publication-title: J Pharmacol Exp Ther – volume: 36 start-page: 164 year: 2002 end-page: 172 article-title: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver publication-title: Hepatology – volume: 44 start-page: 793 year: 2009 end-page: 798 article-title: Expression of OATP1B3 determines uptake of Gd‐EOB‐DTPA in hepatocellular carcinoma publication-title: J Gastroenterol – volume: 158 start-page: 693 year: 2009 end-page: 705 article-title: Impact of OATP transporters on pharmacokinetics publication-title: Br J Pharmacol – volume: 30 start-page: 1042 year: 2009 end-page: 1046 article-title: Liver parenchymal enhancement of hepatocyte‐phase images in Gd‐EOB‐DTPA‐enhanced MR imaging: which biological markers of the liver function affect the enhancement? publication-title: J Magn Reson Imaging – volume: 9 start-page: 61 year: 2009 article-title: Ten years of antibiotic consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in Austria publication-title: BMC Infect Dis – volume: 12 start-page: 649 year: 1984 end-page: 655 article-title: An exact confidence interval for untransformed data for the ratio of two formulation means publication-title: J Pharmacokinet Biopharm – volume: 447 start-page: 653 year: 2004 end-page: 665 article-title: Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties publication-title: Pflugers Arch – volume: 16 start-page: 115 year: 2007 end-page: 123 article-title: Antibiotic use in ambulatory care in Europe (ESAC data 1997–2002): trends, regional differences and seasonal fluctuations publication-title: Pharmacoepidemiol Drug Saf – volume: 30 start-page: 437 year: 2009 end-page: 443 article-title: Detection and characterization of focal hepatic tumors: a comparison of T2‐weighted MR images before and after the administration of gadoxectic acid publication-title: J Magn Reson Imaging – volume: 12 start-page: 153 year: 1987 end-page: 160 article-title: Erythromycin lactobionate: pharmacokinetics and uterine tissue levels publication-title: Eur J Drug Metab Pharmacokinet – volume: 16 start-page: 105 year: 1978 end-page: 109 article-title: Pharmacokinetic study of rifampicin in biliary surgery publication-title: Int J Clin Pharmacol Biopharm – volume: 37 start-page: 680 year: 2002 end-page: 684 article-title: Gadolinium‐ethoxybenzyl‐diethylenetriamine‐pentaacetic acid interaction with clinical drugs in rats publication-title: Invest Radiol – volume: 275 start-page: 23161 year: 2000 end-page: 23168 article-title: Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide publication-title: J Biol Chem – volume: 30 start-page: 849 year: 2009 end-page: 854 article-title: Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd‐EOB‐DTPA)‐enhanced magnetic resonance imaging (MRI) publication-title: J Magn Reson Imaging – year: 2010 – volume: 34 start-page: 1229 year: 2006 end-page: 1236 article-title: Drug‐drug interaction between pitavastatin and various drugs via OATP1B1 publication-title: Drug Metab Dispos – volume: 274 start-page: 17159 year: 1999 end-page: 17163 article-title: Identification of a novel gene family encoding human liver‐specific organic anion transporter LST‐1 publication-title: J Biol Chem – volume: 31 start-page: 356 year: 2010 end-page: 364 article-title: Enhancement of liver parenchyma after injection of hepatocyte‐specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine publication-title: J Magn Reson Imaging – volume: 35 start-page: 779 year: 2007 end-page: 786 article-title: The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3 publication-title: Drug Metab Dispos – volume: 181 start-page: 587 year: 2009 end-page: 592 article-title: Gadoxate‐enhanced T 1‐weighted MR cholangiography: comparison of 1.5 T and 3.0 T publication-title: Rofo – volume: 40 start-page: 715 year: 2005 end-page: 724 article-title: Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths publication-title: Invest Radiol – volume: 5 start-page: 489 year: 2009 end-page: 500 article-title: In vitro evidence for the role of OATP and OCT uptake transporters in drug‐drug interactions publication-title: Expert Opin Drug Metab Toxicol – volume: 230 start-page: 266 year: 2004 end-page: 275 article-title: Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid‐enhanced MR images with intraoperative findings publication-title: Radiology – volume: 282 start-page: 60 year: 2001 end-page: 66 article-title: Abc protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles publication-title: Biochem Biophys Res Commun – volume: 237 start-page: 89 year: 2005 end-page: 98 article-title: Efficacy and safety of MR imaging with liver‐specific contrast agent: U.S. multicenter phase III study publication-title: Radiology – volume: 45 start-page: 689 year: 2005 end-page: 723 article-title: Evaluation of drug‐drug interaction in the hepatobiliary and renal transport of drugs publication-title: Annu Rev Pharmacol Toxicol – volume: 290 start-page: 153 year: 1999 end-page: 157 article-title: Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1 publication-title: J Pharmacol Exp Ther – volume: 195 start-page: 785 year: 1995 end-page: 792 article-title: Phase I clinical evaluation of Gd‐EOB‐DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging publication-title: Radiology – volume: 234 start-page: 468 year: 2005 end-page: 478 article-title: Enhancement of focal liver lesions at gadoxetic acid‐enhanced MR imaging: correlation with histopathologic findings and spiral CT–initial observations publication-title: Radiology – volume: 19 start-page: 171 year: 2004 end-page: 179 article-title: The organic anion transporter (OATP) family publication-title: Drug Metab Pharmacokinet – volume: 34 start-page: 375 year: 2009 end-page: 379 article-title: Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005 publication-title: Int J Antimicrob Agents – volume: 1609 start-page: 1 year: 2003 end-page: 18 article-title: The superfamily of organic anion transporting polypeptides publication-title: Biochim Biophys Acta – volume: 372 start-page: 432 year: 2006 end-page: 443 article-title: Pharmacogenomics of human OATP transporters publication-title: Naunyn Schmiedebergs Arch Pharmacol – ident: e_1_2_6_16_2 – ident: e_1_2_6_34_2 doi: 10.1186/1471-2334-9-61 – ident: e_1_2_6_2_2 doi: 10.1148/radiol.2301020269 – ident: e_1_2_6_11_2 doi: 10.1124/dmd.106.014407 – ident: e_1_2_6_25_2 doi: 10.1007/s00535-009-0056-4 – ident: e_1_2_6_27_2 doi: 10.1111/j.1476-5381.2009.00430.x – ident: e_1_2_6_7_2 doi: 10.1002/jmri.21913 – ident: e_1_2_6_21_2 doi: 10.1146/annurev.pharmtox.44.101802.121444 – ident: e_1_2_6_12_2 doi: 10.1006/bbrc.2001.4318 – ident: e_1_2_6_22_2 doi: 10.1124/jpet.102.041921 – ident: e_1_2_6_20_2 doi: 10.1007/s00210-006-0040-y – ident: e_1_2_6_4_2 doi: 10.1148/radiol.2342040278 – ident: e_1_2_6_13_2 doi: 10.1055/s-0028-1109141 – ident: e_1_2_6_37_2 doi: 10.1111/j.1365-2125.1982.tb01437.x – ident: e_1_2_6_36_2 doi: 10.1007/BF03189891 – ident: e_1_2_6_15_2 doi: 10.1097/01.rli.0000184756.66360.d3 – ident: e_1_2_6_19_2 doi: 10.1016/S0005-2736(02)00633-8 – ident: e_1_2_6_38_2 doi: 10.1124/dmd.106.009290 – ident: e_1_2_6_35_2 doi: 10.1002/pds.1244 – ident: e_1_2_6_33_2 doi: 10.1016/j.ijantimicag.2009.05.008 – ident: e_1_2_6_28_2 doi: 10.1074/jbc.274.24.17159 – ident: e_1_2_6_3_2 doi: 10.1148/radiol.2371031842 – ident: e_1_2_6_17_2 doi: 10.1007/BF01059558 – ident: e_1_2_6_9_2 doi: 10.1148/radiology.183.1.1549695 – ident: e_1_2_6_8_2 doi: 10.1002/jmri.22054 – ident: e_1_2_6_14_2 doi: 10.1148/radiology.195.3.7754011 – ident: e_1_2_6_18_2 doi: 10.1007/s00424-003-1168-y – ident: e_1_2_6_26_2 doi: 10.2133/dmpk.19.171 – ident: e_1_2_6_30_2 doi: 10.1517/17425255.1.3.429 – ident: e_1_2_6_5_2 doi: 10.1002/jmri.21839 – ident: e_1_2_6_10_2 doi: 10.1097/00004424-200212000-00007 – volume: 290 start-page: 153 year: 1999 ident: e_1_2_6_24_2 article-title: Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1 publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)34879-7 – ident: e_1_2_6_6_2 doi: 10.1002/jmri.21956 – ident: e_1_2_6_29_2 doi: 10.1074/jbc.M001448200 – volume: 16 start-page: 105 year: 1978 ident: e_1_2_6_31_2 article-title: Pharmacokinetic study of rifampicin in biliary surgery publication-title: Int J Clin Pharmacol Biopharm – ident: e_1_2_6_32_2 doi: 10.1517/17425250902911463 – ident: e_1_2_6_23_2 doi: 10.1053/jhep.2002.34133 |
| SSID | ssj0009945 |
| Score | 2.104388 |
| Snippet | Purpose
To evaluate if erythromycin compromises liver‐specific enhancement of gadoxetic acid; both compounds competing in organic anion transporting peptides... To evaluate if erythromycin compromises liver-specific enhancement of gadoxetic acid; both compounds competing in organic anion transporting peptides (OATP)... |
| SourceID | proquest pubmed crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 409 |
| SubjectTerms | Adult Contrast Media Drug Interactions erythromycin Erythromycin - administration & dosage Female gadolinium Gadolinium DTPA - administration & dosage gadoxetic acid Humans Liver - anatomy & histology Liver - drug effects magnetic resonance (MR) Magnetic Resonance Imaging Male Organic Anion Transporters - antagonists & inhibitors Reproducibility of Results Sensitivity and Specificity |
| Title | Evaluation of possible drug-drug interaction between gadoxetic acid and erythromycin as an inhibitor of organic anion transporting peptides (OATP) |
| URI | https://api.istex.fr/ark:/67375/WNG-SQ92M129-N/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmri.22458 https://www.ncbi.nlm.nih.gov/pubmed/21274983 https://www.proquest.com/docview/848321392 |
| Volume | 33 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEA-lgvhi_XbVSkARK-z1bjebzUJfirbWwp1aW-yLhMnHtmfb3WPvDlqf_B_0L_QvMZP9OCpF0KddlsmQZGcyk2TmN4Q8F5BCxKAfJix3GxTgIgSIdQiMg9A65ZlH1x-O-M4B2z1MDpfIRpsLU-NDdAduqBl-vUYFBzVdX4CGfj2rxj1ngBLM9B3EHIHz3-wtsKOyzFcodv5DHA5EP-2wSaP1RdNL1ugaTuz5Va7mZc_Vm57tFfKl7XQdcXLSm89UT3_7A8_xf0d1i9xsfFK6WQvRbbJkizvk-rC5db9Lfm51kOC0zOmkRD06tdRU86Nf33_ggyLsRFUnSdAm9osegSnPMUmSgh4bCoWhtrrAwgxnF44zhan75loej5VbVyrkXReZcg0KZDRrkdedfaUTjL8xdkpfvt_c_7B2jxxsb-2_3gmbag6hZtypo821jvJBomJIUfExIxgET2IWMyX6AnKdcZWIlOn-II9UmjOLuyejMuNraN0ny0VZ2IeEGrfvslaYSOSWActFqpRKGDcqThQzPCBr7V-VuoE6x4obp7IGaY4kTrP00xyQZx3tpAb4uJLqhReOjgSqEwyJSxP5efRWfvqYRUPnOclRQGgrPdIpKt6-QGHL-VQKhkWhnDsakAe1VHXMEGWfZSIOyCsvG3_piNwd7r3zb4_-hfgxuVEfhmMczhOyPKvmdtV5UzP11GvNbw8MHe8 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgk4AXvmHh0xIIsUnp2sRxnMcJNrqxFBid2Jvlr2xlW1KlrbTxxP8AfyF_CT47TTU0IcFTouh8Spw735199zuEXjKRioiIbpiQwgYogrJQiFiFglDBlEpp5tD18wHt75Odg-Sgyc2BWhiPD9FuuIFmuPUaFBw2pNcXqKFfT-tRx1qghF1Fy8R6GhB7vd1boEdlmetRbD2IOOyxbtqik0bri7EX7NEyTO3ZZc7mRd_VGZ-tW77D6sRhFkLOyXFnNpUd9e0PRMf__q7b6GbjluINL0d30BVT3kXX8ubg_R76udmiguOqwOMKVOnEYF3PDn99_wEXDMgTta-TwE36Fz4UujqDOkks1EhjUWps6nPozXB6bjljMbHP7MijkbRLSw28fZ8pO6AERtM5-Lo1sXgMKTjaTPDrDxvDj6v30f7W5vBNP2waOoSKUKuRplAqKnqJjEUKug9FwYLRJCYxkazLRKEyKhOWEtXtFZFMC2IggNIy066N1gO0VFalWUFY29DLGKYjVhgiSMFSKWVCqJZxIommAVqd_1auGrRzaLpxwj1Oc8Rhmrmb5gC9aGnHHuPjUqpXTjpaElEfQ1ZcmvAvg3f886csyq3zxAcBwnPx4VZX4QBGlKaaTTgj0BfKeqQBeujFqmUGQPskY3GA1pxw_OVF-E6-t-3uHv0L8XN0vT_Md_nu9uD9Y3TD741DWs4TtDStZ-apda6m8plTod_W4CIO |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELVKK1W8cL-Eq6UiRJGy3U0cx5F4qaBLW9illFb0BVm-lqVtssruSi1P_AN8IV-Cx7msiqpK8JQoGo8SZ8Y-tmfOIPSMiVRERHTDhFi3QBGUhULEKhSECqZUSjPPrj8Y0s19sn2QHCygV00uTMUP0W64gWf48RocfKzt2pw09NtJOeq4CShhV9ASoQ5KACTanZNHZZkvUewARBz2WDdtyUmjtXnbc9PREvTs6UVY8zx09XNP_zr60rx1FXJy1JlNZUd9_4vQ8X8_6wa6VoNSvF5Z0U20YPJbaHlQH7vfRr82Wk5wXFg8LsCRjg3W5ezw94-fcMHAO1FWWRK4Dv7Ch0IXp5AliYUaaSxyjU15BpUZTs6cZiwm7plr-XUk3cBSgu6qypRrkIOiaUO97iZYPIYAHG0m-MWH9b2d1Ttov7-x93ozrMs5hIpQ54_GKhXZXiJjkYLnQ0qwYDSJSUwk6zJhVUZlwlKiuj0bydQSA8snLTPti2jdRYt5kZv7CGu38DKG6YhZQwSxLJVSJoRqGSeSaBqg1eavclVznUPJjWNesTRHHLqZ-24O0EorO64YPi6Ueu6NoxUR5RHExKUJ_zx8yz99zKKBg058GCDcWA93ngrHLyI3xWzCGYGqUA6PBuheZVWtMqDZJxmLA_TS28YlL8K3B7tb_u7Bvwg_Rcs7b_r8_dbw3UN0tdoYh5icR2hxWs7MY4espvKJd6A_Y18gvQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+possible+drug-drug+interaction+between+gadoxetic+acid+and+erythromycin+as+an+inhibitor+of+organic+anion+transporting+peptides+%28OATP%29&rft.jtitle=Journal+of+magnetic+resonance+imaging&rft.au=Huppertz%2C+Alexander&rft.au=Breuer%2C+Josy&rft.au=Fels%2C+Lueder+M&rft.au=Schultze-Mosgau%2C+Marcus&rft.date=2011-02-01&rft.eissn=1522-2586&rft.volume=33&rft.issue=2&rft.spage=409&rft_id=info:doi/10.1002%2Fjmri.22458&rft_id=info%3Apmid%2F21274983&rft.externalDocID=21274983 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1053-1807&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1053-1807&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1053-1807&client=summon |